Massachusetts Chronicle

Myasthenia Gravis Market Predicted To Surpass $2.06 Billion By 2026; Global Key Players: Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer

 Breaking News
  • No posts were found

Myasthenia Gravis Market Predicted To Surpass $2.06 Billion By 2026; Global Key Players: Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer

December 03
13:05 2019
Myasthenia Gravis Market Predicted To Surpass $2.06 Billion By 2026; Global Key Players: Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer

Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research, The global myasthenia gravis (MG) treatment market size was estimated at USD 1.16 billion in 2018 and is anticipated to grow at a CAGR of 7.5% over the forecast period.

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Browse Details of Report, Please Visit @ https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market

North America myasthenia gravis market size by treatment, 2015 - 2026 (USD Million)

Key Takeaways from the report:

  • Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
  • Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
  • North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
  • The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
  • Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Europe myasthenia gravis treatment market share by distribution channel, 2018 (%)

Have Any Query? Ask Our Experts @ https://www.grandviewresearch.com/inquiry/6732/ibb

Grand View Research has segmented the MG treatment market report on the basis of treatment, end use, and region:

Treatment Outlook (Revenue, USD Million, 2015 – 2026)

  • Medication
  • Surgery
  • Others

End Use Outlook (Revenue, USD Million, 2015 – 2026)

  • Hospitals
  • Clinics
  • Others

Regional Outlook (Revenue, USD Million, 2015 – 2026)

  • North America 
    • U.S.
    • Canada
  • Europe 
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific 
    • Japan
    • China
    • India
    • South Korea
    • Singapore
    • Australia
  • Latin America  
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Browse Related Reports :

Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Region, And Segment Forecasts, 2019 – 2026

https://www.grandviewresearch.com/industry-analysis/hunter-syndrome-treatment-market

Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report By Disease (Dengue, Trachoma, Buruli Ulcer, Yaws, Chagas Disease, Leishmaniases), By Product Type And Segment Forecasts, 2019 – 2026

https://www.grandviewresearch.com/industry-analysis/neglected-tropical-disease-treatment-market

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market